StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

EVOK opened at $0.48 on Thursday. The stock’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.93. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42. The firm has a market cap of $4.05 million, a price-to-earnings ratio of -0.21 and a beta of 0.22.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%. The business had revenue of $1.68 million for the quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.